Eupraxia Pharmaceuticals Inc
EPRX
Company Profile
Business description
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
Contact
201 2067 Cadboro Bay Road
VictoriaBCV8R 5G4
CANT: +1 250 590-3968
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
33
Stocks News & Analysis
stocks
Moated ASX player makes moves to support growth in China
a2Milk announced an acquisition and a divestiture as it aims to take a bigger slice of China’s baby formula market.
stocks
Cochlear earnings: Shares overvalued as demand softens
Cochlear’s met expectations, but investors overly optimistic.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,170.00 | 63.50 | -0.69% |
| CAC 40 | 7,884.05 | 39.40 | -0.50% |
| DAX 40 | 24,314.77 | 44.53 | -0.18% |
| Dow JONES (US) | 44,911.82 | 34.30 | -0.08% |
| FTSE 100 | 9,157.74 | 18.84 | 0.21% |
| HKSE | 25,219.39 | 42.54 | 0.17% |
| NASDAQ | 21,629.77 | 6.80 | 0.03% |
| Nikkei 225 | 43,625.92 | 88.39 | -0.20% |
| NZX 50 Index | 12,928.68 | 41.96 | -0.32% |
| S&P 500 | 6,449.15 | 0.65 | -0.01% |
| S&P/ASX 200 | 8,892.70 | 66.60 | -0.74% |
| SSE Composite Index | 3,742.57 | 14.55 | 0.39% |